Monitoring of Effectiveness of Prostaglandin Therapy in Humans
Since the discovery of prostaglandin I2 (PGI2) in 1976 and the reports that this endogenously produced substance is diminished in atherosclerosis, it has been widely used together with PGE1 for the treatment of human atherosclerosis. Most of the therapeutic regimes were based upon Szczeklik’s report  stating that a 72-h continuous intra-arterial infusion results in a clinical benefit in patients suffering from peripheral vascular disease. Owing to the preliminary success prostaglandins were handled with exaggerated enthusiasm without any search for a better therapeutic scheme or for methods allowing the verification of the effect of therapeutic intervention.
KeywordsCitrate Aspirin Prostaglandin Gall PGE1
Unable to display preview. Download preview PDF.
- 1.Fitscha P, Kaliman J, Sinzinger H (1985) Gamma-camera imaging after autologous human platelet labeling with 111In-oxine sulfate: a key for assessing the efficacy of prostacyclin treatment in active atherosclerosis? In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 358–364Google Scholar
- 2.Höfer R, Sinzinger H. Leithner C, Schwarz M, Bergmann H (1981) Experiences with 111In-oxine labelling of autologous platelets in follow-up studies of human kidney transplants. Nucl Med Commun 2: 120Google Scholar
- 6.Sinzinger H, O’Grady J, Fitscha P (1985) Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo. Lancet (submitted)Google Scholar
- 7.Sinzinger H, Fitscha P, Kaliman J, Silberbauer K, O’Grady J (1985) Development of optimal infusion regimes for epoprostenol using radiolabeled platelet uptake over atherosclerotic lesions in man. N Engl J Med (submitted)Google Scholar
- 8.Sinzinger H, O’Grady J, Fitscha P (1985) Platelet deposition on human atherosclerotic lesions is decreased by low dose aspirin in combination with dipyridamole. N Engl J Med (submitted)Google Scholar